Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review

Roderick MacDonald; Michelle Brasure; Philipp Dahm; Carin M. Olson; Torie Nelson; Howard A Fink; Michael C. Risk; Bruce Rwabasonga; Timothy J Wilt

doi:10.1080/13685538.2018.1434503

Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review

Roderick MacDonald, Michelle Brasure, Philipp Dahm, Carin M. Olson, Torie Nelson, Howard A Fink, Michael C. Risk, Bruce Rwabasonga, Timothy J Wilt

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

We conducted a systematic review to evaluate the efficacy and adverse effects of newer drugs used to treat lower urinary tract symptoms (LUTS). The drugs were either Food and Drug Administration (FDA) approved for benign prostatic hyperplasia (BPH) or not FDA approved for BPH but have been evaluated for treatment of BPH since 2008. We searched bibliographic databases through September 2017. We included randomized controlled trials (RCTs) lasting one month or longer published in English. Outcomes of interest were LUTS assessed by validated measures. Efficacy was interpreted using established thresholds indicating clinical significance that identified the minimal detectable difference. Twenty-three unique, generally short-term, RCTs evaluating over 9000 participants were identified. Alpha-blocker silodosin and phosphodiesterase type 5 inhibitor tadalafil were more effective than placebo in improving LUTS (moderate strength evidence) but these drugs had more adverse effects, including abnormal ejaculation (silodosin). Anticholinergics were only effective versus placebo when combined with an alpha-blocker. Evidence was generally low strength or insufficient for other drugs. Evidence was insufficient to assess long-term efficacy, prevention of symptom progression, need for surgical intervention, or long-term adverse effects. Longer trials are needed to assess the effect of these therapies on response rates using established minimal detectable difference thresholds, disease progression, and harms.

Original language	English (US)
Pages (from-to)	1-11
Number of pages	11
Journal	Aging Male
Volume	22
Issue number	1
DOIs	https://doi.org/10.1080/13685538.2018.1434503
State	Published - Jan 2 2019

Bibliographical note

Funding Information:
This project was funded under Contract No. 290-2012-00161-I from the Agency for Healthcare Research and Quality, US Department of Health and Human Services. The authors of this manuscript are responsible for its content. Statements in the manuscript should not be construed as endorsement by the Agency for Healthcare Research and Quality or the US Department of Health and Human Services. The Agency for Healthcare Research and Quality retains a license to display, reproduce, and distribute the data and the report from which this manuscript was derived under the terms of the agency’s contract with the author.

Publisher Copyright:
©, This work was authored as part of the Contributor’s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.

Keywords

5-alpha reductase inhibitor
Lower urinary tract symptoms
alpha blockers
anticholinergic: systematic review
benign prostatic hyperplasia
randomized trials

Publisher link

10.1080/13685538.2018.1434503

Find It

Find It at U of M Libraries

Cite this

@article{9c4097b1e64440c7b5c8e1abba7f686f,

title = "Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review",

abstract = "We conducted a systematic review to evaluate the efficacy and adverse effects of newer drugs used to treat lower urinary tract symptoms (LUTS). The drugs were either Food and Drug Administration (FDA) approved for benign prostatic hyperplasia (BPH) or not FDA approved for BPH but have been evaluated for treatment of BPH since 2008. We searched bibliographic databases through September 2017. We included randomized controlled trials (RCTs) lasting one month or longer published in English. Outcomes of interest were LUTS assessed by validated measures. Efficacy was interpreted using established thresholds indicating clinical significance that identified the minimal detectable difference. Twenty-three unique, generally short-term, RCTs evaluating over 9000 participants were identified. Alpha-blocker silodosin and phosphodiesterase type 5 inhibitor tadalafil were more effective than placebo in improving LUTS (moderate strength evidence) but these drugs had more adverse effects, including abnormal ejaculation (silodosin). Anticholinergics were only effective versus placebo when combined with an alpha-blocker. Evidence was generally low strength or insufficient for other drugs. Evidence was insufficient to assess long-term efficacy, prevention of symptom progression, need for surgical intervention, or long-term adverse effects. Longer trials are needed to assess the effect of these therapies on response rates using established minimal detectable difference thresholds, disease progression, and harms.",

keywords = "5-alpha reductase inhibitor, Lower urinary tract symptoms, alpha blockers, anticholinergic: systematic review, benign prostatic hyperplasia, randomized trials",

author = "Roderick MacDonald and Michelle Brasure and Philipp Dahm and Olson, {Carin M.} and Torie Nelson and Fink, {Howard A} and Risk, {Michael C.} and Bruce Rwabasonga and Wilt, {Timothy J}",

note = "Funding Information: This project was funded under Contract No. 290-2012-00161-I from the Agency for Healthcare Research and Quality, US Department of Health and Human Services. The authors of this manuscript are responsible for its content. Statements in the manuscript should not be construed as endorsement by the Agency for Healthcare Research and Quality or the US Department of Health and Human Services. The Agency for Healthcare Research and Quality retains a license to display, reproduce, and distribute the data and the report from which this manuscript was derived under the terms of the agency{\textquoteright}s contract with the author. Publisher Copyright: {\textcopyright}, This work was authored as part of the Contributor{\textquoteright}s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.",

year = "2019",

month = jan,

day = "2",

doi = "10.1080/13685538.2018.1434503",

language = "English (US)",

volume = "22",

pages = "1--11",

journal = "Aging Male",

issn = "1368-5538",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia

T2 - a systematic review

AU - MacDonald, Roderick

AU - Brasure, Michelle

AU - Dahm, Philipp

AU - Olson, Carin M.

AU - Nelson, Torie

AU - Fink, Howard A

AU - Risk, Michael C.

AU - Rwabasonga, Bruce

AU - Wilt, Timothy J

N1 - Funding Information: This project was funded under Contract No. 290-2012-00161-I from the Agency for Healthcare Research and Quality, US Department of Health and Human Services. The authors of this manuscript are responsible for its content. Statements in the manuscript should not be construed as endorsement by the Agency for Healthcare Research and Quality or the US Department of Health and Human Services. The Agency for Healthcare Research and Quality retains a license to display, reproduce, and distribute the data and the report from which this manuscript was derived under the terms of the agency’s contract with the author. Publisher Copyright: ©, This work was authored as part of the Contributor’s official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.

PY - 2019/1/2

Y1 - 2019/1/2

N2 - We conducted a systematic review to evaluate the efficacy and adverse effects of newer drugs used to treat lower urinary tract symptoms (LUTS). The drugs were either Food and Drug Administration (FDA) approved for benign prostatic hyperplasia (BPH) or not FDA approved for BPH but have been evaluated for treatment of BPH since 2008. We searched bibliographic databases through September 2017. We included randomized controlled trials (RCTs) lasting one month or longer published in English. Outcomes of interest were LUTS assessed by validated measures. Efficacy was interpreted using established thresholds indicating clinical significance that identified the minimal detectable difference. Twenty-three unique, generally short-term, RCTs evaluating over 9000 participants were identified. Alpha-blocker silodosin and phosphodiesterase type 5 inhibitor tadalafil were more effective than placebo in improving LUTS (moderate strength evidence) but these drugs had more adverse effects, including abnormal ejaculation (silodosin). Anticholinergics were only effective versus placebo when combined with an alpha-blocker. Evidence was generally low strength or insufficient for other drugs. Evidence was insufficient to assess long-term efficacy, prevention of symptom progression, need for surgical intervention, or long-term adverse effects. Longer trials are needed to assess the effect of these therapies on response rates using established minimal detectable difference thresholds, disease progression, and harms.

AB - We conducted a systematic review to evaluate the efficacy and adverse effects of newer drugs used to treat lower urinary tract symptoms (LUTS). The drugs were either Food and Drug Administration (FDA) approved for benign prostatic hyperplasia (BPH) or not FDA approved for BPH but have been evaluated for treatment of BPH since 2008. We searched bibliographic databases through September 2017. We included randomized controlled trials (RCTs) lasting one month or longer published in English. Outcomes of interest were LUTS assessed by validated measures. Efficacy was interpreted using established thresholds indicating clinical significance that identified the minimal detectable difference. Twenty-three unique, generally short-term, RCTs evaluating over 9000 participants were identified. Alpha-blocker silodosin and phosphodiesterase type 5 inhibitor tadalafil were more effective than placebo in improving LUTS (moderate strength evidence) but these drugs had more adverse effects, including abnormal ejaculation (silodosin). Anticholinergics were only effective versus placebo when combined with an alpha-blocker. Evidence was generally low strength or insufficient for other drugs. Evidence was insufficient to assess long-term efficacy, prevention of symptom progression, need for surgical intervention, or long-term adverse effects. Longer trials are needed to assess the effect of these therapies on response rates using established minimal detectable difference thresholds, disease progression, and harms.

KW - 5-alpha reductase inhibitor

KW - Lower urinary tract symptoms

KW - alpha blockers

KW - anticholinergic: systematic review

KW - benign prostatic hyperplasia

KW - randomized trials

UR - http://www.scopus.com/inward/record.url?scp=85060171573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060171573&partnerID=8YFLogxK

U2 - 10.1080/13685538.2018.1434503

DO - 10.1080/13685538.2018.1434503

M3 - Review article

C2 - 29394114

AN - SCOPUS:85060171573

SN - 1368-5538

VL - 22

SP - 1

EP - 11

JO - Aging Male

JF - Aging Male

IS - 1

ER -

Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this